How ALGINAGRAFT™ is designed to work
ALGINAGRAFT™ is a bone graft composition concept in which particulate bone graft material is carried within a calcium-crosslinked alginate hydrogel and supplied as a pre-portioned unit, so that the graft is handled as one piece rather than as loose particles. Everything on this page describes design objectives. None of them has been demonstrated in bench, preclinical or clinical testing.
The composition, in three parts
1. Particulate bone graft
The regenerative component is particulate bone graft material. The carrier concept is being developed to be compatible with different classes of particulate graft; which material will be used in the first configuration is a development decision that has not been published. Nothing on this site should be read as a claim about a specific graft material.
2. Alginate hydrogel matrix
Sodium alginate is a polysaccharide extracted from the cell walls of brown algae. In the presence of calcium ions it forms a hydrogel by ionic crosslinking at room temperature. The design intent is that the gel holds the graft particles in a hydrated, cohesive mass during handling and placement. The matrix contains no collagen, gelatin or other animal- or human-derived carrier.
3. Pre-portioned unit
The composition is intended to be manufactured in predetermined quantities and geometries, so that a clinician selects a unit for the anticipated defect instead of measuring, hydrating and mixing loose material chairside. The concept includes pre-formed unit geometries. No claim is made regarding the dimensional stability of an augmented site.
Intended use sequence under development
Open the pack → place the unit into the prepared site → shape to the defect contour → close. This is the sequence the composition is being designed for. Time and step counts have not been measured, and handling characteristics have not been evaluated.
Documented challenges — and what the design is trying to address
The left column is what the peer-reviewed literature documents about particulate grafts. The right column is what ALGINAGRAFT™ is being developed to address. The right column is a list of objectives, not results.
| Documented challenge with particulate grafts (cited literature) | ALGINAGRAFT™ development objective (not demonstrated) |
|---|---|
| «A key limitation of particulate grafts is their susceptibility to displacement» — loosely packed particles «are susceptible to compression under flap tension». Zuercher et al., Clinical Oral Implants Research, 2026 (PMC13542762). | To keep graft particles together as a single unit during placement, membrane positioning and closure. |
| Separated particulates and powders «have exhibited poor handling properties and space maintenance characteristics». Frontiers in Bioengineering and Biotechnology, 2023 (PMC10282947). | To supply a cohesive unit that can be grasped, transferred and shaped chairside. |
| «The packing of augmentation material is critical when non-standardized defects are treated», with intraalveolar voids reported after augmentation. Materials, 2024 (PMC10817230). | To provide predetermined volumes and geometries for common defect types. |
| Migration of xenograft particles into the maxillary sinus described in case reports. International Journal of Implant Dentistry, 2022 (PMC8936023). | To allow controlled placement through a lateral window as one cohesive mass. |
| Commercial putty carriers such as collagen, glycerol and CMC resorb within days, with subsequent collapse of the particle scaffold. Calder et al., Advanced Healthcare Materials, 2025 (PMID 39840481). | To investigate a calcium-crosslinked alginate matrix as an alternative carrier. Its resorption profile has not been characterized for this composition. |
What has not been evaluated
Handling characteristics. Hydration behaviour and moisture retention during placement. Behaviour under irrigation and suction. Dimensional stability of the unit and of the augmented site. Resorption profile of the alginate matrix in the oral environment. Interaction between the matrix and different particle types. Sterilization method and shelf life. Any clinical outcome. Each of these is a development task, and the evidence page lists what the literature says about alginate carriers, including results that cut against the concept.
Proposed indications under development
Not cleared for any indication. The proposed uses being considered are the bone-augmentation procedures in which particulate graft is used today: extraction socket preservation, guided bone regeneration beneath a barrier membrane, horizontal and vertical alveolar ridge augmentation, sinus floor elevation, selected periodontal osseous defects, and bone-regenerative procedures in oral and maxillofacial surgery. Whether the composition is suitable for any of them will be determined by testing and by the regulatory pathway described on the development status page.
Research directions outside the current design
Separately from ALGINAGRAFT™ as currently designed, Meddent Innovative Concepts is interested in whether alginate matrices can serve as carriers for other agents, and in patient-specific unit geometries derived from imaging. These are research questions, not features. No product incorporating additional agents is under development for market, and no claims are made regarding them.
Why this matters to a clinician
Two facts from the public record frame the project. In the FDA device registry, a putty form accounts for 1.9% of dental bone-graft listings in active distribution and 11.9% of orthopedic bone-void-filler listings — dentistry still works largely with loose particulate. And every collagenated or putty-form dental graft cleared in the United States today uses a carrier of bovine, porcine or human origin, or a synthetic polymer; none uses alginate. The Journal documents both facts with the queries behind them.